Big Pharma Bets on Body’s Garbage-Disposal System to Beat Cancer
At their most basic level, many of the deadliest diseases are caused by nests of misguided proteins. Most medicines work by attaching themselves to these proteins and temporarily shutting them down. In the 1990s, Yale University scientist Craig Crews and a colleague had a radical idea: What if a drug could destroy a bad protein by making it a target of the body’s own molecular trash disposal machines?
Rothlin Is Appointed McConnell Duberg Professor
Carla Vanina Rothlin, PhD, newly named as Dorys McConnell Duberg Professor of Immunobiology, studies the mechanisms that regulate the magnitude and resolution of the immune response. Rothlin is also a professor of pharmacology, a member of the Yale Cancer Center, and a Howard Hughes Faculty Scholar.
Celebrating Cancer Survivorship
Greenwich, CT (June 10, 2019) – Appearances by cancer survivors and an MLB All-Star player were among the highlights at Greenwich Hospital’s annual “Swing into Survivorship” celebration, which drew more than 175 former patients, volunteers and oncology staff from Smilow Cancer Hospital’s Greenwich Hospital Campus to pay tribute to cancer survivors.
Yale Cancer Center researchers find genetic explanations behind the rapid spread of ovarian cancer
In a breakthrough study, Yale Cancer Center (YCC) researchers have defined the genetic characteristics of primary, metastatic and recurrent ovarian tumors and evaluated new targeted therapies to treat the disease. The findings are reported today in the Proceedings of the National Academy of Science (PNAS) online early edition.
Top 50: Studies at Yale led to chemotherapy field
The year was 1942. The country was in the middle of World War II and two Yale pharmacologists were hired by the Department of Defense to study the effects of nitrogen gas as a therapeutic agent. The project was top secret, and pharmacologists Alfred Gilman, Ph.D., a faculty member at the Department of Pharmacology, and Dr. Louis S. Goodman, a faculty member at the Yale School of Medicine, were studying whether mustard agents could be used to stop the growth of rapidly dividing cells such as cancer cells. While Gilman and Goodman were able to utilize nitrogen gas in a positive way, when it was unleashed on the battlefield in World War I, it was one of the deadliest chemical weapons available. “Nitrogen mustard had a couple of uses,” said Dr. Roy Herbst, chief of Medical Oncology at Yale Cancer Center and Smilow Cancer Hospital. “Not only for positive use, as we use it in cancer - it’s not used so much anymore - but it was used in wartime, as chemical warfare.”
Wedding Rigorous Scientific Methodology and Ancient Herbal Wisdom to Benefit Cancer Patients: The Development of PHY906
Our own studies of traditional Chinese medicine began in the early 2000s, when we sought to answer the question of whether there was a Chinese herbal medicine that could prevent and/or reduce the gastrointestinal toxicities associated with irinotecan-based chemotherapy. Around that time, the combination of irinotecan, fluorouracil (5-FU), and leucovorin (IFL) was being developed as a frontline treatment regimen, and it was associated with a 25% to 30% incidence of grade 3 or 4 gastrointestinal toxicity. With this in mind, Professor Yung-Chi Cheng, PhD, and his research team at Yale University reviewed the Chinese literature and identified Huang Qin Tang as a classic formula that has been widely used in China and other Asian countries to treat gastrointestinal disorders.
Researchers develop novel immunotherapy to target colorectal cancer
A Yale-led research team has developed an antibody that blocks tumors in animal models of colorectal cancer. If the finding is confirmed in clinical trials, the antibody-based treatment could become an effective weapon against colorectal cancer, and possibly other cancers, that resist current immunotherapies, the researchers said.
Crystallizing discovery on a key target for cancer drugs
Many approved cancer therapies target a protein called epidermal growth factor receptor (EGFR) that regulates many crucial cellular processes and can speed the proliferation of tumor cells. Yale Cancer Center scientists now have made a fundamental discovery about EGFR signaling, reported in the journal Cell, that may open the potential for new types of cancer drugs.
Can a cancer drug treat a rare cardiac disease?
A study by a Yale scientis suggests that dasatinib and similar drugs at low doses could be effective treatment for cardiovascular defects related to Noonan syndrome (NS), a genetic disorder that results in severe heart defects, and should be considered for clinical trials.
Researchers find genes behind aggressive ovarian and endometrial cancers
In a major breakthrough for ovarian and uterine cancers, Yale researchers have defined the genetic landscape of rare, highly aggressive tumors called carcinosarcomas (CSs), pointing the way to possible new treatments. The findings are published in the Oct. 10 online early edition of Proceedings of the National Academy of Sciences.
CaSB@Yale launches with $9.5M federal grant to battle deadliest cancers
Yale University researchers across a spectrum of disciplines are coming together to fight some of the deadliest forms of cancer with a novel approach that has gained support from the National Cancer Institute (NCI) of the National Institutes of Health (NIH).